Corrigendum to “Comparison of the clinical efficacy between tigecycline plus extended-infusion imipenem and sulbactam plus imipenem against ventilator-associated pneumonia with pneumonic extensively drug-resistant Acinetobacter baumannii bacteremia, and correlation of clinical efficacy with in vitro synergy tests” [J Microbiol Immunol Infect (2015) 924–933]

Similar Items

• Corrigendum to “Comparison of commonly used antimicrobial susceptibility testing methods for evaluating susceptibilities of clinical isolates of Enterobacteriaceae and nonfermentative Gram-negative bacilli to cefoperazone-sulbactam” [J Microbiol Immunol Infect (2017) 50: 454–463]
  by: Shio-Shin Jean, et al.
  Published: (2018-04-01)
• Interaction of imipenem and tigecycline against carbapenem-resistant acinetobacter baumanii: the relativity of synergism
  by: Alfizah, H., et al.
  Published: (2015)
• Efficacy and safety of tigecycline monotherapy vs. imipenem/cilastatin in Chinese patients with complicated intra-abdominal infections: a randomized controlled trial
  by: Chen Xiaoping, et al.
  Published: (2010-07-01)
• Comparison in a rat thigh abscess model of imipenem, meropenem and cefoperazone-sulbactam against <it>Acinetobacter baumannii </it>strains in terms of bactericidal efficacy and resistance selection
  by: Gundes Sibel, et al.
  Published: (2004-01-01)
• Upstream region of OprD mutations in imipenem-resistant and imipenem-sensitive Pseudomonas isolates
  by: Masoumeh Kiani, et al.
  Published: (2021-06-01)